substantial, long-lasting effectiveness against the current Delta version and other common SARS-CoV-2 viral strains. Furthermore, the data revealed that the immune response was durable for at least eight months, which is the time period tested till now. The preprint research reports were submitted to the BioRxiv, which is a charitable preprint server for the biological sciences.
According to the reports, Johnson & Johnson’s vaccine was 85 percent efficacious against serious disease in the ensemble trial, and it provided security against hospitalization and death. The vaccination was consistently efficacious in all regions investigated across the world, including South Africa and Brazil, where fast growing Beta and Zeta strains were prevalent during the study period.
Vice Chairman of the Executive Committee and Chief Scientific Officer at Johnson & Johnson, Paul Stoffels, MD, expressed…
